<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084383</url>
  </required_header>
  <id_info>
    <org_study_id>J9988</org_study_id>
    <secondary_id>R01CA088058</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J9988</secondary_id>
    <nct_id>NCT00084383</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas</brief_title>
  <official_title>A Safety and Efficacy Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected With the GM-CSF Gene in Combination With Adjuvant Chemoradiotherapy for the Treatment of Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from gene-modified pancreatic cancer cells may make the body build&#xD;
      an immune response to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil,&#xD;
      work in different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
      Radiation therapy uses high-energy x-rays to damage tumor cells. Giving vaccine therapy&#xD;
      together with chemotherapy and radiation therapy after surgery may kill any remaining tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving vaccine therapy together with&#xD;
      adjuvant chemoradiotherapy works in treating patients with resected stage I or stage II&#xD;
      adenocarcinoma (cancer) of the pancreas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine overall and disease-free survival of patients with resected stage I or II&#xD;
           adenocarcinoma of the pancreas treated with adjuvant chemoradiotherapy in combination&#xD;
           with GVAX pancreatic cancer vaccine.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate specific in vivo parameters of immune response (post-vaccination delayed-type&#xD;
           hypersensitivity reactions to autologous tumor, mesothelin-specific T-cell response, and&#xD;
           the degree of local eosinophil, macrophage, and T-cell infiltration at the vaccine site)&#xD;
           with clinical responses in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxic effects associated with intradermal injections of this vaccine in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
        -  Post surgery vaccination: Within 8-10 weeks after pancreaticoduodenectomy, patients&#xD;
           receive GVAX pancreatic cancer vaccine intradermally (ID) on day 0.&#xD;
&#xD;
        -  Adjuvant chemoradiotherapy: Within 16-28 days after the first vaccination, patients&#xD;
           receive fluorouracil (5-FU) IV continuously for 3 weeks. Approximately 1-2 weeks after&#xD;
           completion of 5-FU, patients receive chemoradiotherapy comprising radiotherapy daily and&#xD;
           5-FU IV continuously for 26-28 weeks. Approximately 3-5 weeks after completion of&#xD;
           chemoradiotherapy, patients receive 5-FU IV continuously for 4 weeks. 5-FU repeats every&#xD;
           6 weeks for 2 courses.&#xD;
&#xD;
        -  Post chemoradiotherapy vaccination: Within 4-8 weeks after the completion of&#xD;
           chemoradiotherapy, patients receive GVAX pancreatic cancer vaccine ID on days 0, 28, 56,&#xD;
           and 196.&#xD;
&#xD;
      Treatment continues in the absence of unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Participants were followed for the duration of the study, an average of 2 years</time_frame>
    <description>Overall survival in patients treated with adjuvant chemoradiotherapy in sequence with the irradiated allogeneic GM-CSF transfected pancreatic tumor cell lines. Overall survival is defined as time from surgery until death, regardless of cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Participants were followed for the duration of the study, an average of 2 years</time_frame>
    <description>Disease-free Survival in Patients Treated With Adjuvant Chemoradiotherapy in Sequence With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines. DFS is defined as time from surgery until clinical evidence of disease (eg, CT scan) or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Further Identify and Characterize Toxicities Associated With Intradermal Injections of the Vaccine That Were Initially Reported in the Phase 1 Trial.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the Association of Specific in Vivo Parameters of Immune Response With Clinical Responses in Patients Treated With Combination Chemoradiotherapy Together With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines.</measure>
    <time_frame>Continuous</time_frame>
    <description>The specific immune parameters include: post-vaccination delayed type hypersensitivity reactions to autologous tumor and the degree of local eosinophil, macrophage, and T cell infiltration at the vaccine site, and mesothelin-specific T cell responses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>GVAX pancreatic cancer vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth &quot;booster&quot; vaccination, six months following the fourth vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GVAX pancreatic cancer vaccine</intervention_name>
    <description>Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth &quot;booster&quot; vaccination, six months following the fourth vaccination.</description>
    <arm_group_label>GVAX pancreatic cancer vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive ductal adenocarcinoma of the head, neck, and&#xD;
             uncinate process of the pancreas&#xD;
&#xD;
               -  Mixed adenocarcinoma tumors allowed if the predominant invasive component of the&#xD;
                  tumor is adenocarcinoma&#xD;
&#xD;
               -  Stage I or II (clinical stage T1-3, N0-1, M0) disease&#xD;
&#xD;
          -  Has undergone pancreaticoduodenectomy at the Johns Hopkins Hospital within the past&#xD;
             8-10 weeks&#xD;
&#xD;
               -  Completely resected (R0) or microscopic residual (R1) disease&#xD;
&#xD;
          -  No diagnosis other than ductal adenocarcinoma, including any of the following:&#xD;
&#xD;
               -  Adenosquamous&#xD;
&#xD;
               -  Squamous cell&#xD;
&#xD;
               -  Colloid&#xD;
&#xD;
               -  Islet cell&#xD;
&#xD;
               -  Non-invasive intraductal papillary mucinous neoplasms&#xD;
&#xD;
               -  Serous or mucinous cystadenoma or cystadenocarcinoma&#xD;
&#xD;
               -  Carcinoid&#xD;
&#xD;
               -  Small or large cell carcinoma&#xD;
&#xD;
               -  Intraductal oncocytic papillary neoplasms&#xD;
&#xD;
               -  Osteoclast-like giant cell tumors&#xD;
&#xD;
               -  Acinar cell carcinoma&#xD;
&#xD;
               -  Pancreatoblastoma&#xD;
&#xD;
               -  Solid pseudopapillary tumors&#xD;
&#xD;
               -  Undifferentiated small cell carcinoma&#xD;
&#xD;
               -  Non-epithelial tumors (sarcoma, gastrointestinal stromal tumor, or lymphoma)&#xD;
&#xD;
               -  Adenocarcinoma of the ampulla&#xD;
&#xD;
               -  Adenocarcinoma of the distal bile duct&#xD;
&#xD;
               -  Adenocarcinoma of the duodenum&#xD;
&#xD;
          -  No recurrent disease&#xD;
&#xD;
          -  No metastatic disease, including peritoneal implants or liver and/or lung involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt;/= 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;/= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;/= 10 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt;/= 2 mg/dL&#xD;
&#xD;
          -  AST/ALT &lt;/= 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &lt;/= 5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt;/= 2 mg/dL&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No asthma or chronic obstructive pulmonary disease requiring systemic corticosteroids&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No prior or concurrent autoimmune disease requiring treatment with systemic&#xD;
             immunosuppressants, including any of the following:&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Systemic vasculitis&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Psoriasis&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Hemolytic anemia or immune thrombocytopenia&#xD;
&#xD;
               -  Rheumatoid arthritis&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Sjogren's syndrome&#xD;
&#xD;
               -  Sarcoidosis&#xD;
&#xD;
          -  Negative results to viral delayed-type hypersensitivity serology testing if autologous&#xD;
             tumor cells are available&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No postoperative complications (e.g., inability to take oral nutrition &gt;/= 1,500&#xD;
             calories/day, ongoing requirement for long-term biliary stenting, or persistence of&#xD;
             wound infection)&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  No uncontrolled medical conditions that would preclude study participation&#xD;
&#xD;
          -  No other major active medical or psychosocial problem that could be exacerbated by&#xD;
             study treatment&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 4 weeks&#xD;
             after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 1 month since prior biologic therapy&#xD;
&#xD;
          -  No other concurrent biologic therapy, immunotherapy, or gene therapy for pancreatic&#xD;
             cancer&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 1 month since prior chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy for pancreatic cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 28 days since prior systemic steroids&#xD;
&#xD;
          -  No concurrent systemic corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 1 month since prior radiotherapy&#xD;
&#xD;
          -  No other concurrent radiotherapy for pancreatic cancer&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 1 month since prior participation in an investigational new drug trial&#xD;
&#xD;
          -  No other concurrent investigational therapy for pancreatic cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel A. Laheru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <results_first_submitted>March 1, 2013</results_first_submitted>
  <results_first_submitted_qc>June 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 15, 2013</results_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>duct cell adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GVAX Pancreatic Cancer Vaccine</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GVAX Pancreatic Cancer Vaccine</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="9.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall survival in patients treated with adjuvant chemoradiotherapy in sequence with the irradiated allogeneic GM-CSF transfected pancreatic tumor cell lines. Overall survival is defined as time from surgery until death, regardless of cause.</description>
        <time_frame>Participants were followed for the duration of the study, an average of 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GVAX Pancreatic Cancer Vaccine</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival in patients treated with adjuvant chemoradiotherapy in sequence with the irradiated allogeneic GM-CSF transfected pancreatic tumor cell lines. Overall survival is defined as time from surgery until death, regardless of cause.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="21.2" upper_limit="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Further Identify and Characterize Toxicities Associated With Intradermal Injections of the Vaccine That Were Initially Reported in the Phase 1 Trial.</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate the Association of Specific in Vivo Parameters of Immune Response With Clinical Responses in Patients Treated With Combination Chemoradiotherapy Together With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines.</title>
        <description>The specific immune parameters include: post-vaccination delayed type hypersensitivity reactions to autologous tumor and the degree of local eosinophil, macrophage, and T cell infiltration at the vaccine site, and mesothelin-specific T cell responses.</description>
        <time_frame>Continuous</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival</title>
        <description>Disease-free Survival in Patients Treated With Adjuvant Chemoradiotherapy in Sequence With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines. DFS is defined as time from surgery until clinical evidence of disease (eg, CT scan) or death due to any cause.</description>
        <time_frame>Participants were followed for the duration of the study, an average of 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GVAX Pancreatic Cancer Vaccine</title>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Disease-free Survival in Patients Treated With Adjuvant Chemoradiotherapy in Sequence With the Irradiated Allogeneic GM-CSF Transfected Pancreatic Tumor Cell Lines. DFS is defined as time from surgery until clinical evidence of disease (eg, CT scan) or death due to any cause.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" lower_limit="14.6" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>GVAX Pancreatic Cancer Vaccine</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Cancer related</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Biliary Obstruction, secondary to progessive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophils, elevated</sub_title>
                <counts group_id="E1" events="30" subjects_affected="17" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <description>Localized vaccine site reaction</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Localized vaccine site reaction</description>
                <counts group_id="E1" events="172" subjects_affected="60" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <description>Localized vaccine site reaction</description>
                <counts group_id="E1" events="171" subjects_affected="60" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <description>Localized vaccine site reaction</description>
                <counts group_id="E1" events="152" subjects_affected="51" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <description>Localized vaccine site reaction</description>
                <counts group_id="E1" events="142" subjects_affected="55" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vaccine site flare</sub_title>
                <description>Localized vaccine site reaction</description>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Laheru</name_or_title>
      <organization>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>410-955-8974</phone>
      <email>laherda@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

